Compare Adaptive Biotechnologies Corp (ADPT) vs Global X Autonomous & Electric Vehicles (DRIV) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Global X Autonomous & Electric Vehicles — how do they compare? Adaptive Biotechnologies Corp trades at $19.96 (market cap $3.33B), while Global X Autonomous & Electric Vehicles trades at $35.55. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, Global X Autonomous & Electric Vehicles nearer its low. Which is the better fit depends on your goals.
| ADPT | DRIV | |
|---|---|---|
Market Cap | $3.33B | — |
Sector | Health | Sector/Thematic |
52-Week High | $22.37 | $42.53 |
52-Week Low | $10.24 | $23.67 |
Enterprise Value | $3.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
DRIV trades at $37.63, up 2.42% today, but technical signals are bearish with moving averages indicating selling pressure. The stock faces industry headwinds from shifting consumer demand and geopolitical tensions affecting fuel prices. Recent news highlights competitive threats from Chinese EV makers and regulatory uncertainties in the U.S. market, while a dividend of $0.07 is scheduled for July 2026.
Outlook remains cautious due to bearish technicals and sector volatility. Investment opportunities lie in exposure to autonomous driving and EV growth, but risks include intense competition, regulatory changes, and macroeconomic pressures. Wall Street sentiment is mixed, reflecting the ETF's diversified tech and auto holdings amid evolving market dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Global X Autonomous & Electric Vehicles
DRIV invests in companies involved in autonomous driving and electric vehicle production. It tracks the Solactive Autonomous & Electric Vehicles Index, focusing on software and hardware leaders like Tesla, NVIDIA, and Microsoft.
Read more on DRIV →
